Omnicell Targets $2.4B Revenue by 2031 Through High-Margin SaaS Strategy
Omnicell generates $1.18 billion in revenue and is shifting from hardware to software-led offerings with a goal of doubling sales to $2.4 billion by 2031 through high-margin SaaS and Expert Services. Recurring revenue represents nearly 50% of total and margins are forecast to expand from low teens to mid-20s.
1. Business Model Shift
Omnicell currently generates $1.18 billion in annual revenue and is transitioning away from hardware sales toward a software-led model. The company aims to double top-line sales to $2.4 billion by 2031, driven by high-margin SaaS subscriptions and Expert Services deliverables, which should underpin margin expansion.
2. Strategic Acquisitions and Revenue
The October 2025 ANiGENT acquisition broadened Omnicell’s capabilities in drug diversion detection and bolstered its recurring revenue streams. With nearly 50% of revenue now subscription- or service-based, the company is also executing tuck-in deals and debt reduction to strengthen its balance sheet and support margin growth.
3. Autonomous Pharmacy Vision and Competitive Position
Omnicell is advancing toward an “Autonomous Pharmacy” where AI and robotics handle all medication workflows, leveraging over 900 patents and a large installed base for proprietary analytics. While competitors like Becton Dickinson remain threats, high switching costs and continuous innovation could justify a rerating if ARR exceeds $1.5 billion and the business is valued as healthcare IT.